• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初诊时发生骨转移的非小细胞肺癌的预后因素。

Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

出版信息

Lung Cancer. 2012 Sep;77(3):572-7. doi: 10.1016/j.lungcan.2012.05.094. Epub 2012 Jun 4.

DOI:10.1016/j.lungcan.2012.05.094
PMID:22672969
Abstract

INTRODUCTION

The skeletal system is one of the most common distant sites of metastatic non-small cell lung cancer (NSCLC) which may lead to skeletal-related event (SRE). The purpose of this study was to assess the frequency of SRE and the prognostic factors of overall survival (OS) in patients presenting bone metastasis in NSCLC.

METHODS

Two hundred and twenty NSCLC patients with skeletal metastases at the time of diagnosis between January 2000 and August 2007 were investigated retrospectively.

RESULTS

Forty-seven of 110 patients (43%) without a SRE at the time of diagnosis experienced their first SRE during the follow-up. Patients with squamous cell carcinoma had a 1.8-times higher risk of short OS [95% confidence interval (CI) 1.11-2.84, p=0.016], compared with patients with non-squamous cell carcinoma, and patients treated with EGFR TKIs achieved a 50% protective effect in OS compared with patients not treated with them (95% CI 0.32-0.80, p=0.004). Patients with ECOG performance status 0-1 and single bone metastasis had a 1.8-times (95% CI 1.13-2.60, p=0.003) and 2.4-times (95% CI 1.26-4.46, p=0.008) longer OS than patients with performance status≥2 and two or more bone metastases, respectively.

CONCLUSION

Our study demonstrated that the frequency of SRE was common and single bone metastasis, good performance status (ECOG 0, 1), EGFR TKI treatment had good prognosis and histology of squamous cell carcinoma had bad prognosis.

摘要

简介

骨骼系统是转移性非小细胞肺癌(NSCLC)最常见的远处转移部位之一,可能导致骨骼相关事件(SRE)。本研究旨在评估 NSCLC 骨转移患者 SRE 的发生频率和总生存(OS)的预后因素。

方法

回顾性分析 2000 年 1 月至 2007 年 8 月期间诊断时有骨骼转移的 220 例 NSCLC 患者。

结果

110 例无 SRE 患者中有 47 例在随访期间首次发生 SRE。与非鳞癌患者相比,鳞癌患者的 OS 较短风险增加 1.8 倍[95%置信区间(CI)1.11-2.84,p=0.016],与未接受 EGFR TKI 治疗的患者相比,接受 EGFR TKI 治疗的患者的 OS 保护作用增加 50%(95% CI 0.32-0.80,p=0.004)。ECOG 表现状态 0-1 和单发骨转移的患者 OS 分别增加 1.8 倍(95% CI 1.13-2.60,p=0.003)和 2.4 倍(95% CI 1.26-4.46,p=0.008),而表现状态≥2 和两个或更多骨转移的患者则较短。

结论

本研究表明,SRE 的发生频率较高,单发骨转移、良好的表现状态(ECOG 0、1)、EGFR TKI 治疗和鳞癌组织学具有良好的预后,而表现状态较差和多发骨转移则预后较差。

相似文献

1
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.初诊时发生骨转移的非小细胞肺癌的预后因素。
Lung Cancer. 2012 Sep;77(3):572-7. doi: 10.1016/j.lungcan.2012.05.094. Epub 2012 Jun 4.
2
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.接受化疗的非小细胞肺癌患者发生骨相关事件的危险因素。
Lung Cancer. 2009 Aug;65(2):219-22. doi: 10.1016/j.lungcan.2008.10.026. Epub 2008 Dec 10.
3
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.骨转移非小细胞肺癌患者骨骼相关事件的预测因素。
Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.
4
Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.非小细胞肺癌骨转移患者发生骨相关事件(SREs)的危险因素及影响无SRE生存的因素。
Tumour Biol. 2016 Jan;37(1):1131-40. doi: 10.1007/s13277-015-3907-z. Epub 2015 Aug 15.
5
Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective.转移性非小细胞肺癌的人群特征及预后因素:福克斯蔡斯癌症中心的回顾性研究
Clin Lung Cancer. 2008 Mar;9(2):116-21. doi: 10.3816/CLC.2008.n.018.
6
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.同步寡转移非小细胞肺癌(NSCLC)的根治性治疗:患者结局和预后因素。
Lung Cancer. 2013 Oct;82(1):95-102. doi: 10.1016/j.lungcan.2013.07.023. Epub 2013 Aug 6.
7
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.唑来膦酸和锶-89 治疗非小细胞肺癌无症状骨转移患者的临床意义。
Clin Lung Cancer. 2013 May;14(3):254-60. doi: 10.1016/j.cllc.2012.09.001. Epub 2012 Oct 25.
8
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?表皮生长因子受体突变型非小细胞肺癌患者:更易发生骨和脑转移?
Lung Cancer. 2014 Apr;84(1):86-91. doi: 10.1016/j.lungcan.2014.01.006. Epub 2014 Jan 23.
9
[Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].[IV期非小细胞肺癌患者放疗后的生存状况——附287例报告]
Ai Zheng. 2006 Nov;25(11):1419-22.
10
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.非小细胞肺癌患者在现代化疗时代的脑膜转移的临床结果。
Lung Cancer. 2012 Jun;76(3):387-92. doi: 10.1016/j.lungcan.2011.11.022. Epub 2011 Dec 18.

引用本文的文献

1
Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study.免疫检查点抑制剂治疗后肺癌骨转移患者的预后因素:一项回顾性研究
World J Orthop. 2024 Dec 18;15(12):1155-1163. doi: 10.5312/wjo.v15.i12.1155.
2
Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with -mutated non-small-cell lung cancer: a retrospective, multicenter cohort study.股骨骨转移是表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗的伴有突变的非小细胞肺癌患者的不良预后因素:一项回顾性多中心队列研究。
Ther Adv Med Oncol. 2024 Dec 20;16:17588359241303090. doi: 10.1177/17588359241303090. eCollection 2024.
3
Construction and Verification of Nomogram Model for Lung Adenocarcinoma With ≤ 5 Bone-Only Metastases Basing on Hematology Markers.
基于血液学标志物构建及验证≤5处单纯骨转移肺腺癌的列线图模型
Front Oncol. 2022 Jun 1;12:858634. doi: 10.3389/fonc.2022.858634. eCollection 2022.
4
Transcriptome Sequencing reveals the expressed profiles of mRNA and ncRNAs and regulate network via ceRNA mediated molecular mechanism of lung adenocarcinoma bone metastasis in Xuanwei.转录组测序揭示了宣威肺腺癌骨转移中mRNA和非编码RNA的表达谱以及通过ceRNA介导的分子机制调控网络。
Transl Cancer Res. 2021 Jan;10(1):73-87. doi: 10.21037/tcr-20-2376.
5
Estimating survival and clinical outcome in advanced non-small cell lung cancer with bone-only metastasis using molecular markers.使用分子标志物评估仅发生骨转移的晚期非小细胞肺癌的生存率和临床结局。
J Bone Oncol. 2021 Oct 12;31:100394. doi: 10.1016/j.jbo.2021.100394. eCollection 2021 Dec.
6
Prognostic factors for bone metastases from head and neck squamous cell carcinoma: A case series of 97 patients.头颈部鳞状细胞癌骨转移的预后因素:97例病例系列研究
Mol Clin Oncol. 2021 Nov;15(5):246. doi: 10.3892/mco.2021.2408. Epub 2021 Sep 27.
7
Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.肺癌同步骨转移:来自中国天津单中心 15716 例患者的回顾性研究。
BMC Cancer. 2021 May 26;21(1):613. doi: 10.1186/s12885-021-08379-2.
8
Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors.接受表皮生长因子受体抑制剂治疗的非小细胞肺癌患者发生骨转移的预后较差。
J Bone Oncol. 2021 May 4;29:100369. doi: 10.1016/j.jbo.2021.100369. eCollection 2021 Aug.
9
Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.非小细胞肺癌骨转移患者的临床特征和预后因素。
J Int Med Res. 2020 May;48(5):300060520925644. doi: 10.1177/0300060520925644.
10
Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis.诊断时伴有骨转移的小细胞肺癌患者的临床结局。
J Bone Oncol. 2019 Nov 2;19:100265. doi: 10.1016/j.jbo.2019.100265. eCollection 2019 Dec.